CHF 35.00
In stock
AG-CN2-0455-M01010 mgCHF 35.00
AG-CN2-0455-M05050 mgCHF 80.00
AG-CN2-0455-M250250 mgCHF 240.00
More Information
Product Details
Product Type Chemical


MW 248.3
Merck Index 14: 7048
CAS 20554-84-1
RTECS LY4220000
Source/Host Chemicals Isolated from Magnolia grandiflora.
Purity Chemicals ≥98% (HPLC)
Appearance White to light green solid.
Solubility Soluble in DMSO, ethanol or dichloromethane. Insoluble in water.
Identity Determined by 1H-NMR.
Smiles C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Anticancer and antiangiogenic compound. Induces apoptosis, cell cycle arrest and autophagy in various cancer cell lines.
  • At low concentrations acts as antioxidant reducing oxidative stress generated through the TCR signaling pathway. At high concentration induces O2- and causes oxidative-stress-mediated apoptosis.
  • Potent anti-inflammatory and anti-atherosclerotic agent.
  • NF-κB inhibitor by directly targeting IκB kinase.
  • Inhibits STAT-mediated anti-apoptotic gene transcription.
  • NLRP3 inflammasome inhibitor. Inhibits ATPase activity of NLRP3 and protease activity of caspase 1.
  • Directly binds the pattern recognition receptor NOD2.
  • Specifically inhibits HDAC1 without affecting other class I/II HDACs.
  • DNA methyltransferase 1 (DNMT1) inhibitor.
  • Induces ubiquitination of MDM2 resulting in the activation of p53 and other MDM2-regulated tumor suppressor proteins.
  • VEGF inhibitor. Reduces the expression of VEGF and its receptors VEGRF1 and 2.
  • Inhibits tubulin carboxypeptidase (TCP) activity.
  • Microtubule-interfering compound, inhibiting cell migration and tubule formation.
  • Anti-leishmanial and anti-trypanosomal agent.
  • Partial TRPA1 agonist.
Product References
  1. Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide: R.M. Wiedhopf, et al.; J. Pharm. Sci. 62, 345 (1973)
  2. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase: B.H. Kwok, et al.; Chem. Biol. 8, 759 (2001)
  3. Cell cycle effects and caspase-dependent and independent death of HL-60 and Jurkat cells treated with the inhibitor of NF-kappaB parthenolide: P. Pozarowski, et al.; Cell Cycle 2, 377 (2003)
  4. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium: T.S. Tiuman, et al.; Antimicrob. Agents Chemother. 49, 176 (2005)
  5. Dual role of the anti-inflammatory sesquiterpene lactone: regulation of life and death by parthenolide: M. Li-Weber, et al.; Cell Death Differ. 12, 408 (2005)
  6. Parthenolide inhibits tubulin carboxypeptidase activity: X. Fonrose, et al.; Cancer Res. 67, 3371 (2007)
  7. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated: Y.N. Gopal, et al.; Chem. Biol. 14, 813 (2007)
  8. Trypanosoma cruzi: antiprotozoal activity of parthenolide obtained from Tanacetum parthenium (L.) Schultz Bip. (Asteraceae, Compositae) against epimastigote and amastigote forms: E. Izumi, et al.; Exp. Parasitol. 118, 324 (2008)
  9. Modulation of DNA methylation by a sesquiterpene lactone parthenolide: Z. Liu, et al.; J. Pharmacol. Exp. Ther. 329, 505 (2009)
  10. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions: Y.N. Gopal, et al.; Mol. Cancer Ther. 8, 552 (2009)
  11. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome: C. Juliana, et al.; J. Biol. Chem. 285, 9792 (2010)
  12. Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals: L. Zhao, et al.; Nutr. Rev. 69, 310 (2011) (Review)
  13. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities: V.B. Mathema, et al.; Inflammation 35, 560 (2012) (Review)
  14. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel: S. Materazzi, et al.; Pain 154, 2750 (2013)
  15. Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer: S.L. Kim, et al.; Int. J. Mol. Med. 33, 1261 (2014)
  16. Parthenolide-induced apoptosis, autophagy and suppression of proliferation in HepG2 cells: J. Sun, et al.; Asian Pac. J. Cancer Prev. 15, 4897 (2014)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.